Exicure, Inc. — Department of Defense SBIR Phase II: AuraSense Therapeutics is developing oligonucleotide-modified gold nanoparticles called Sp
Exicure, Inc. — SBIR Phase II award from Department of Defense.
- Amount
- $986,621
- Agency
- Department of Defense · Defense Advanced Research Projects Agency
- Program / Phase
- SBIR · Phase II
- Solicitation
- 2012.1
- NAICS
- —
- Place of performance
- IL
- Period
- 2013-08-01 → 2015-07-31
Description
AuraSense Therapeutics is developing oligonucleotide-modified gold nanoparticles called Spherical Nucleic Acid (SNA) constructs, which are a powerful new way of regulating cellular gene expression. AuraSense Therapeutics will use SNAs as genetically programmable antimicrobial agents in a manner to provide a rapid and effective way to develop next-generation antibacterial agents. The outcome of this work will be a new approach to generating bactericides: a genetically programmable rapidly adaptable nanoparticle therapeutic (RANT). The strategy is designed to be rapidly re-programmed to counter microbial threats, both natural and engineered.